Your current location is set to United States. If this is incorrect, please change your location:
Summary: Therapy efficacy is evaluated using clinical measures in patients with MS, however these measures change slowly and are difficult to measure objectively, therefore clinical trials examining progression in multiple sclerosis (MS) require a very large number of people and long period of time... Read the full article
Summary: The onset of MS prior to age 18, during pivotal periods of cognitive maturation and development, has a profound impact on the child and their family. A fundamental unmet need is to understand the impact of pediatric-onset MS (POMS) and the recently identified myelin oligodendrocyte glycoprotein... Read the full article
Summary: One of the unmet needs is a better understanding of, and treatment options for, progression in MS. While current therapies in MS aim to slow the progression of the disease, there are no treatment options that successfully alter the trajectory of progression. A key to altering progression in... Read the full article
Summary: Damage to myelin and the underlying nerve fibers (also called axons) may contribute to progression in MS. This research aims to develop a single novel MRI technique that can identify the different types of tissue damage in MS (myelin and axonal damage). This research may help to identify non-invasive... Read the full article
